The identified signature genes (RPS13, MRPS5, MRPL21, MRPL22, NDUFS3) not only unravel the molecular cascade linking maternal hyperglycemia to fetal vascular dysfunction but also offer tangible targets for diagnostic and therapeutic innovation. The gene discussed is MRPL21; the disease is Hyperglycemia.